SCHEMBL2851464

SCHEMBL2851464

O=C1CCCC=C1C(O)c1cncc(-c2ccccc2Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
ALOX15 P16050 3/20 0.37
CYP3A4 P08684 1/20 0.37
CTSA P10619 3/20 0.36
CYP2C19 P33261 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
HIF1A Q16665 1/20 0.34
AVPR2 P30518 1/20 0.34
AVPR1A P37288 1/20 0.34
TP53 P04637 1/20 0.33
USP7 Q93009 1/20 0.32
KCNA5 P22460 1/20 0.31
MAPT P10636 2/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31
BRD4 O60885 1/20 0.31
POLB P06746 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853280 0.93 ALDH1A1 (0.41) THRBCTSAALDH1A1AVPR2AVPR1A
SCHEMBL2849070 0.72 THRB (0.43) THRBALOX15CYP3A4CYP2C19ALDH1A1
SCHEMBL5792543 0.72 THRB (0.64) THRBALOX15CYP3A4CYP2C19ALDH1A1
SCHEMBL14400222 0.70 THRB (0.65) THRBALOX15CYP3A4CYP2C19ALDH1A1
SCHEMBL3550335 0.70 THRB (0.44) THRBALOX15CYP3A4CYP2C19ALDH1A1
SCHEMBL2851463 0.68 THRB (0.42) THRBALOX15CYP3A4CYP2C19ALDH1A1
SCHEMBL3557158 0.65 EGFR (0.38) CTSAAVPR2AVPR1AUSP7KCNA5
SCHEMBL2853092 0.65 ALDH1A1 (0.42) THRBALDH1A1
SCHEMBL2855535 0.64 ALDH1A1 (0.44) THRBALDH1A1
SCHEMBL2878634 0.64 CYP2C19 (0.39) THRBALOX15CYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US claimed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP claimed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof HBS1L, SSBP1, QARS1 THRB 4830/4885ALOX15 2838/4885CYP3A4 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.